UK-based GW Pharmaceuticals has started a Phase III clinical trial of Epidiolex (cannabidiol or CBD) to treat Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.

The company obtained orphan drug designation from the US Food and Drug Administration (FDA) for Epidiolex to treat LGS in 2014.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

GW Pharmaceuticals CEO Justin Gover said: "The commencement of this Phase III pivotal trial of Epidiolex in Lennox-Gastaut syndrome follows on from the recent start of two Phase III pivotal trials of Epidiolex in Dravet syndrome and represents another important milestone towards our planned submission of a NDA to the FDA in 2016.

"Although there are approved treatments available for patients with Lennox-Gastaut syndrome, this severe form of epilepsy often remains particularly difficult to treat. We believe that Epidiolex has the potential to meet this significant unmet need."

The study is a randomised, double-blind and 14-week comparison of Epidiolex against placebo in a total of 150 patients to evaluate the dose-ranging safety and efficacy of the Epidiolex as an adjunctive antiepileptic treatment.

The trial will include three arms of 50 patients, comprising 20mg/kg and 10mg/kg of Epidiolex and placebo.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to the company, the primary measure of this study will be the percentage change from baseline.

GW will also analyse several additional efficacy and safety secondary outcome measures of the study and is expected to release top-line data from this trial in early 2016.